Abbott to Acquire Novel Investigational Biologic to take care of Chronic Pain Abbott announced a definitive contract to obtain the global rights to PanGenetics BV’s PG110 fully humanized antibody to Nerve Development Factor , expanding the company’s pain treatment portfolio and leveraging its expertise in biologics vardenafil side effects . PG110 is normally a novel biologic in Phase I clinical trial development that targets NGF for the treating chronic pain. NGF is definitely released at sites of tissue inflammation and damage, and plays a significant role in the transmitting of pain indicators by the central nervous system. The goal for treatment of chronic discomfort continues to be potent, long-lasting analgesia that is tolerable for patients without the potential for dependence and abuse, stated John Leonard, M.D., senior vice president, global development and research, Abbott.
Essential presentations are the following : SPIRIT IV: Two-year outcomes from SPIRIT IV will be provided by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the first late-breaking medical trials session at 11 a.m. On Thursday in the Main Arena, Sept. 23. SPIRIT IV is among the largest randomized clinical trials ever executed that compares two drug eluting stents. Dr. Stone is the principal investigator of the SPIRIT IV trial. SPIRIT III: Four-year results from SPIRIT III will become presented during the Scientific Symposia beginning at 1 p.m. On Wednesday, Sept. 22. SPIRIT III is a potential, multi-center, randomized, single-blind, controlled medical trial evaluating XIENCE V to TAXUS in 1,002 patients with either one or two de novo coronary artery lesions.